Qiagen NV (QGEN)
41.61
+0.53
(+1.29%)
USD |
NYSE |
Apr 26, 13:22
Qiagen Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | -125.80M |
| September 30, 2022 | 389.60M |
| June 30, 2022 | -94.34M |
| March 31, 2022 | -120.17M |
| December 31, 2021 | -150.37M |
| September 30, 2021 | -212.31M |
| June 30, 2021 | -77.21M |
| March 31, 2021 | -100.36M |
| December 31, 2020 | -50.13M |
| September 30, 2020 | -60.04M |
| June 30, 2020 | -121.38M |
| March 31, 2020 | -149.29M |
| December 31, 2019 | -639.08M |
| September 30, 2019 | -108.30M |
| June 30, 2019 | -148.32M |
| March 31, 2019 | -117.80M |
| December 31, 2018 | 360.41M |
| September 30, 2018 | -66.34M |
| June 30, 2018 | 313.47M |
| March 31, 2018 | 629.44M |
| December 31, 2017 | 387.19M |
| September 30, 2017 | 391.21M |
| June 30, 2017 | 42.71M |
| March 31, 2017 | -251.08M |
| December 31, 2016 | -10.60M |
| Date | Value |
|---|---|
| September 30, 2016 | -12.23M |
| June 30, 2016 | -0.77M |
| March 31, 2016 | -80.23M |
| December 31, 2015 | -258.61M |
| September 30, 2015 | -299.91M |
| June 30, 2015 | -315.50M |
| March 31, 2015 | -265.94M |
| December 31, 2014 | 192.84M |
| September 30, 2014 | 211.56M |
| June 30, 2014 | 221.73M |
| March 31, 2014 | 247.79M |
| December 31, 2013 | -68.76M |
| September 30, 2013 | 95.24M |
| June 30, 2013 | 103.66M |
| March 31, 2013 | 175.25M |
| December 31, 2012 | 226.60M |
| September 30, 2012 | -162.32M |
| June 30, 2012 | -239.78M |
| March 31, 2012 | -304.90M |
| December 31, 2011 | -310.63M |
| September 30, 2011 | -62.41M |
| June 30, 2011 | -38.21M |
| March 31, 2011 | -31.76M |
| December 31, 2010 | -35.23M |
| September 30, 2010 | 52.18M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-639.08M
Minimum
Dec 2019
389.60M
Maximum
Sep 2022
-117.83M
Average
-120.17M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
| MoonLake Immunotherapeutics | 479.70M |
| LENZ Therapeutics Inc | -- |
| Thermo Fisher Scientific Inc | -3.622B |
| uniQure NV | 362.72M |
| ProQR Therapeutics NV | -2.463M |